Market closed
OptiNose/$OPTN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About OptiNose
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Ticker
$OPTN
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
128
Website
OptiNose Metrics
BasicAdvanced
$93M
-
-$2.12
-0.31
-
Price and volume
Market cap
$93M
Beta
-0.31
52-week high
$9.60
52-week low
$4.93
Average daily volume
172K
Financial strength
Current ratio
0.773
Quick ratio
0.681
Long term debt to equity
-3.053
Total debt to equity
-319.527
Interest coverage (TTM)
-0.81%
Management effectiveness
Return on assets (TTM)
-8.62%
Return on equity (TTM)
33.93%
Valuation
Price to revenue (TTM)
1.191
Price to book
-2.29
Price to tangible book (TTM)
-2.29
Price to free cash flow (TTM)
-2.081
Growth
Revenue change (TTM)
10.20%
Earnings per share change (TTM)
-55.34%
3-year revenue growth (CAGR)
1.57%
3-year earnings per share growth (CAGR)
-53.95%
OptiNose News
AllArticlesVideos
OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN
Business Wire·4 weeks ago
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of Shareholders
GlobeNewsWire·4 weeks ago
OPTN Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of OptiNose, to Paratek Pharmaceuticals
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for OptiNose stock?
OptiNose (OPTN) has a market cap of $93M as of April 20, 2025.
What is the P/E ratio for OptiNose stock?
The price to earnings (P/E) ratio for OptiNose (OPTN) stock is 0 as of April 20, 2025.
Does OptiNose stock pay dividends?
No, OptiNose (OPTN) stock does not pay dividends to its shareholders as of April 20, 2025.
When is the next OptiNose dividend payment date?
OptiNose (OPTN) stock does not pay dividends to its shareholders.
What is the beta indicator for OptiNose?
OptiNose (OPTN) has a beta rating of -0.31. This means that it has an inverse relation to market volatility.